🇺🇸·20h agoIndustry
FT839: A Multi-Antigen Targeting Off-the-Shelf Dual-CAR T Cell for the Treatment of Pathogenic B and T Cells in Autoimmune Diseases
Publisher
F
Fate Therapeutics
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on fatetherapeutics.com
Leave the platform to read the original full article on the publisher site.
Source: Fate Therapeutics
Scope: Industry
Related coverage
More related coverage
EMS Pharma News·18h ago
POLÍTICA DE PRIVACIDADE
Fate Therapeutics·20h ago
Off-the-Shelf Anti-CD19 CAR T-cell Therapy With Reduced or No Conditioning Chemotherapy Demonstrates Efficacy and Tolerability in Systemic Lupus Erythematosus: Meaningful Activity Supports Planned Adolescent Enrollment
Fate Therapeutics·20h ago
Safety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy With Reduced Conditioning in SLE: A Phase 1 Study
Fate Therapeutics·20h ago